A SWITCH TO BELATACEPT-BASED IMMUNOSUPPRESIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS FROM CALCINEURIN INHIBITORS (CNI) HAS A FAVOURABLE SAFETY PROFILE AND RESULTS IN IMPROVED RENAL FUNCTION: 12-MONTH RESULTS FROM A PHASE II STUDY
IMMUNOLOGY AND CELL BIOLOGY（2011）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要